Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENDULUM: Ketamine Sedation for aSAH
NCT05032118Phase 3Withdrawn
- Start
- Apr 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, single-blind trial in aneurysmal subarachnoid hemorrhage (SAH) comparing Ketamine with Standard of Care (2 arms). Primary endpoint: Incidence of moderate and severe radiographic cerebral vasospasm (CV). Planned start Apr 2023; status: withdrawn.
02
Drugs
ketamine
03
Conditions
aneurysmal subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT05032118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032118.